Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18159576 | 0.81 | KDM4E (0.46) | MAPTKDM4EALDH1A1PDE4DLMNA | |
| SCHEMBL3069598 | 0.77 | KDM4E (0.58) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL25461666 | 0.76 | KDM4E (0.40) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL12202411 | 0.74 | TOP1 (0.36) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL25461641 | 0.74 | MEN1 (0.41) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL25461665 | 0.72 | KDM4E (0.35) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL24701074 | 0.71 | KDM4E (0.41) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL18159534 | 0.71 | MAOA (0.46) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL18159531 | 0.71 | MAOA (0.46) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL16801042 | 0.71 | MAOA (0.46) | MAPTKDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20190280218-A1 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2019-09-12 | — | — | US | disclosed |
| US-10374170-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2019-08-06 | — | — | US | disclosed |
| US-20160308146-A1 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20160308146-A1 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11917913-B2 | Substituted oxepines | OXGR1, OXTR, OCIAD2 | MAPT 1547/4885KDM4E 710/4885MEN1 2568/4885 |
| US-10374170-B2 | Substituted oxepines | OXGR1, OXTR, OCIAD2 | MAPT 1547/4885KDM4E 710/4885MEN1 2568/4885 |
| US-20190280218-A1 | SUBSTITUTED OXEPINES | OXGR1, OXTR, OCIAD2 | MAPT 1547/4885KDM4E 710/4885MEN1 2568/4885 |
| US-20160308146-A1 | SUBSTITUTED OXEPINES | OXGR1, OXTR, OCIAD2 | MAPT 1547/4885KDM4E 710/4885MEN1 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.